encorafenib and Carcinoma--Neuroendocrine

The limited knowledge of the molecular alterations that characterize poorly differentiated neuroendocrine carcinomas has limited the clinical development of targeted agents directed to driver mutations. Here we aim to identify new molecular targets in colon neuroendocrine carcinomas (co-NEC) and proof the efficacy of matching drugs.. We performed a multi-omic analysis of co-NEC to identify genetic or epigenetic alterations that could be exploited as effective drug targets. We compared co-NEC samples with colorectal carcinomas (CRC) to identify neuroendocrine-specific traits. Patients with co-NEC and patient-derived xenografts were treated with a BRAFV600E-blocking drug to demonstrate sensitivity.. co-NEC and CRC are similar in their mutational repertoire, although co-NECs are particularly enriched in. The identification of

Topics: Animals; Carbamates; Carcinoma, Neuroendocrine; Cetuximab; Colonic Neoplasms; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays